Arriving in the landscape of excess body fat therapy, retatrutide presents a unique approach. Unlike many current medications, retatrutide operates as a dual agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. This concurrent engagement promotes various advantag